Sign In
Buy SLDB
$8.79
+0.490 (+5.90%)
At Close: Jun 23, 2026
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
07:08pm, Monday, 08'th Jun 2026
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Jun 2026
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ca
Solid Biosciences to Participate at Upcoming Investor Conferences
08:00am, Monday, 01'st Jun 2026
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
04:08pm, Tuesday, 12'th May 2026
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agenc
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
08:00am, Thursday, 07'th May 2026
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global re
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st May 2026
CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and car
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
08:00am, Thursday, 30'th Apr 2026
- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid B
- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy -
Solid Biosciences to Participate at Upcoming Investor Conferences
08:00am, Tuesday, 07'th Apr 2026
CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neur
Solid Biosciences (NASDAQ:SLDB) Stock Price Up 5.5% on Analyst Upgrade
02:46am, Friday, 27'th Mar 2026
Shares of Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) shot up 5.5% on Thursday after Truist Financial upgraded the stock to a strong-buy rating. The stock traded as high as $7.61 and last
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of “Moderate Buy” by Brokerages
02:22am, Monday, 23'rd Mar 2026
Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) has received an average recommendation of "Moderate Buy" from the twelve research firms that are currently covering the company, MarketBeat Rati
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
04:12pm, Thursday, 19'th Mar 2026
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003
Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB
03:31am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC cut its stake in shares of Solid Biosciences Inc. (NASDAQ: SLDB) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
08:02pm, Thursday, 12'th Mar 2026
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start
03:00pm, Thursday, 12'th Mar 2026
Solid Biosciences retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne Muscular Dystrophy [DMD]. The company demonstrated 60% mean microdystrophin expression
